June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Practice Preferences in Treatment of Retinopathy of Prematurity (ROP)
Author Affiliations & Notes
  • Kirstin Tawse
    Ophthalmology, New England Eye Center at Tufts Medical Center, Boston, MA
  • Karen W Jeng
    School of Medicine, Robert Wood Johnson, New Brunswick, NJ
  • Caroline R Baumal
    Ophthalmology, New England Eye Center at Tufts Medical Center, Boston, MA
  • Footnotes
    Commercial Relationships Kirstin Tawse, None; Karen Jeng, None; Caroline Baumal, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4318. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kirstin Tawse, Karen W Jeng, Caroline R Baumal; Practice Preferences in Treatment of Retinopathy of Prematurity (ROP). Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4318.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To evaluate current practice patterns regarding therapy for retinopathy of prematurity (ROP) and characterize factors influencing clinical decisions.


A database of all ophthalmologists subspecializing in pediatrics and retina from the AAO, subspecialty societies and academic hospital information in the United States was compiled. An anonymous survey was emailed to obtain information regarding demographics, treatment practices and hypothetical clinical scenarios. Responses were analyzed using Fisher’s exact test.


From 2977 subspecialists identified, 647 (21.7%) completed the survey and 323 physicians self-reported as treating ROP in the last 5 years. ROP treaters consisted of 79% retina and 21% pediatric ophthalmology fellowship trained. 55% of ROP treaters perform intravitreal anti-VEGF injection for ROP with 78% utilizing bevacizumab and 22% using ranibizumab. The largest deterrent to anti-VEGF therapy from the options given was uncertainty regarding long term side effects reported by 65%. 18% responded that difficulty obtaining pediatric anesthesia and/or operating room access was an obstacle to laser treatment, while 64% reported there were no barriers to performing laser. For stage 3 ROP in zone 1 with plus disease, 54% favored initial anti-VEGF treatment while 42% preferred initial laser. Laser was the preferred initial treatment for 57% of respondents for stage 2 ROP in posterior zone 2 with plus, and for 81% of respondents for stage 3 ROP in mid zone 2 with plus. Geographic practice location was significantly associated with the use of anti-VEGF treatment of ROP (p=0.019); respondents from the South were most likely to elect to use anti-VEGF agents. Subspecialty training and length of time in practice were not significantly associated with treatment preferences.


Anti-VEGF injection is considered for initial therapy of posterior threshold ROP by over 50 percent of respondents in this survey. Geographic location was the only notable factor influencing treatment preferences. Concerns by clinicians regarding potential anti-VEGF side effects merit further investigation.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.